Reuters
Danish pharmaceutical company Bavarian Nordic said on Wednesday a U.S. Centers for Disease Control and Prevention panel has voted in favor of recommending the routine use of Jynneos vaccine for adults at risk of mpox. The CDC's Advisory Committee on Immunization Practices (ACIP) voted to recommend that individuals 18 years and older with certain risk factors should receive two doses of Jynneos. The panel had previously recommended the vaccine for individuals at risk of mpox only during an outbreak, Bavarian said.